- Abatacept (NON-FORMULARY)
- Abciximab
- Acetaminophen
- Acetylcysteine
- Acyclovir
- Adalimumab (NON-FORMULARY)
- Adenosine
- Alcohol
- Alglucosidase alfa (NON-FORMULARY)
- Alprostadil
- Alteplase
- Albumin (BLOOD PRODUCT from TML)
- Amikacin
- Agalsidase beta (NON-FORMULARY)
- Aminophylline
- Amiodarone
- Ammonul (SPECIAL ACCESS PROGRAM)
- Amoxicillin-Clavulanate
- Amphotericin-B
- Amphotericin B Lipid Complex (NON-FORMULARY)
- Amphotericin B Liposomal
- Ampicillin sodium
- Anakinra (NON-FORMULARY)
- Anti-thymocyte globulin Equine (eATG) and Anti-thymocyte globulin Rabbit (rATG)
- Arginine hydrochloride
- Arsenic trioxide
- Artesunate (SPECIAL ACCESS PROGRAM)
- Atracurium (NON-FORMULARY)
- Atropine
- AzaCITIDine (NON-FORMULARY)
- AzaTHIOprine
- Azithromycin dihydrate
- Baclofen
- Benztropine mesylate
- Bevacizumab (NON-FORMULARY or INVESTIGATIONAL)
- Bleomycin
- Bortezomib
- Brentuximab vedotin
- Bretylium tosylate
- Bendamustine (NON-FORMULARY)
- Bupivacaine HCl
- CARBOplatin
- Calcitriol
- Calcium disodium edetate
- Blinatumomab
- Calcium gluconate
- Canakinumab (NON-FORMULARY)
- Carmustine
- Caspofungin
- Brivaracetam
- CeFAZolin
- CefTRIAXone sodium
- Cefotaxime sodium
- Cefoxitin sodium (NON-FORMULARY)
- Ceftazidime
- Cefuroxime
- Chorionic gonadotropin
- Cidofovir (SPECIAL ACCESS PROGRAM)
- Cilengitide (INVESTIGATIONAL)
- ChlorproMAZINE HCl
- Ciprofloxacin
- Cisatracurium
- CISplatin
- Cixutumamab (INVESTIGATIONAL)
- Cladribine (NON-FORMULARY)
- Clindamycin phosphate
- Clofarabine (COMMERCIAL or INVESTIGATIONAL)
- Clomipramine (SPECIAL ACCESS PROGRAM)
- Cloxacillin sodium
- Colistimethate sodium
- Cosyntropin
- CPX-351 (DAUNOrubicin & Cytarabine liposome) (Study supply; NON-FORMULARY)
- Cyanocobalamin
- DACTINomycin
- CycloSPORINE
- Cyclophosphamide
- DAUNOrubicin
- Cytarabine
- Dacarbazine
- DAPTOmycin
- Daclizumab (NON-FORMULARY)
- Cytomegalovirus immune globulin, human (BLOOD PRODUCT from TML)
- Dalteparin (NON-FORMULARY)
- Dantrolene sodium
- Daratumumab (NON-FORMULARY)
- Darbepoetin
- Deferoxamine mesylate
- Defibrotide (NON-FORMULARY)
- Desmopressin acetate
- Dexamethasone
- Dexmedetomidine HCL
- Dexrazoxane (NON-FORMULARY)
- Dextran (STORES PRODUCT)
- Dextrose (STORES PRODUCT)
- Diazepam
- Diazepam emulsion (NON-FORMULARY)
- Diazoxide
- Digoxin
- Dinutuximab (SPECIAL ACCESS PROGRAM)
- DimenhyDRINATE
- DOXOrubicin
- DiphenhydrAMINE
- DOBUTamine
- DOPamine
- Dihydroergotamine Mesylate
- Doxycycline (SPECIAL ACCESS PROGRAM)
- Emapalumab (NON-FORMULARY)
- Eculizumab (NON-FORMULARY)
- Edrophonium chloride
- Erwinia L-Asparaginase
- Enalaprilat
- Enoxaparin
- Epirubicin (NON-FORMULARY)
- Dupilumab (NON-FORMULARY)
- EPHEDrine sulfate
- EPINEPHrine HCl
- Drisapersen (SPECIAL ACCESS PROGRAM)
- Epoprostenol
- Erythromycin lactobionate
- Esmolol
- Estrogen, Conjugated
- Etoposide
- Ethacrynic acid
- Etoposide phosphate (SPECIAL ACCESS PROGRAM)
- Famotidine
- Fat emulsion 20%
- FentaNYL citrate
- Filgrastim
- Fluconazole
- Fludarabine (NON-FORMULARY)
- Flumazenil
- Fluorouracil
- Flupenthixol decanoate (NON-FORMULARY)
- Folic acid
- Fomepizole
- Fosaprepitant (STUDY DRUG)
- Foscarnet (SPECIAL ACCESS PROGRAM)
- Fosphenytoin
- Furosemide
- Ganciclovir
- Gemcitabine
- Gemtuzumab Ozogamicin (NON FORMULARY)
- Gentamicin sulphate
- Glucagon
- Glucarpidase (SPECIAL ACCESS PROGRAM)
- Galsulfase
- Glycopyrrolate
- Golimumab (NON-FORMULARY)
- Ganitumab (INVESTIGATIONAL)
- Gonadorelin acetate
- Granisetron hydrochloride
- Guanethidine (SPECIAL ACCESS PROGRAM)
- HYDROmorphone
- Haloperidol base
- Heparin sodium
- Hu 14.18-IL2 Fusion Protein (INVESTIGATIONAL)
- Hyaluronidase (SPECIAL ACCESS PROGRAM)
- HydrALAZINE HCl
- Hydrocortisone sodium succinate
- Hydroxocobalamin
- Hydroxyzine HCl (NON-FORMULARY)
- IDArubicin
- Ifosfamide
- Imiglucerase
- InFLIXimab
- Imipenem + cilastatin sodium (NON-FORMULARY)
- Immune globulin, human (BLOOD PRODUCT from TML)
- Inotuzumab (NON-FORMULARY, INVESTIGATIONAL)
- Hyoscine butylbromide (NON-FORMULARY)
- Insulin, regular
- Irinotecan
- Interferon alfa-2b
- Idarucizumab (STUDY DRUG)
- Iron sucrose (NON-FORMULARY)
- Isoproterenol HCl
- Ketamine HCl
- Ketorolac tromethamine
- Labetalol
- Laronidase (NON-FORMULARY)
- Leucovorin calcium
- KRN23 (STUDY DRUG)
- LevETIRAcetam
- Levocarnitine (NON-FORMULARY)
- Levofloxacin
- Levothyroxine
- Lidocaine hydrochloride
- Lacosamide
- Linezolid (NON-FORMULARY)
- LORazepam
- Loxapine Hydrochloride
- Magnesium sulfate
- Mannitol
- MedroxyPROGESTERone acetate
- Meperidine HCl
- Meropenem
- Mesna
- Methotrexate
- Methadone (SPECIAL ACCESS PROGRAM)
- Methotrimeprazine
- MethylPREDNISolone sodium succinate
- Methylene Blue
- Methylnaltrexone (NON-FORMULARY)
- Metoclopramide HCl
- Midazolam
- MetroNIDAZOLE
- Milrinone
- MitoMYcin
- Mivacurium (NON-FORMULARY)
- MitoXANTRONE
- Morphine sulfate
- Mycophenolate mofetil (NON-FORMULARY)
- Nalbuphine
- Naloxone HCl
- Nelarabine (INVESTIGATIONAL)
- Neostigmine methylsulfate
- Nitroglycerin
- Nitroprusside sodium (SPECIAL ACCESS PROGRAM)
- Nivolumab
- Norepinephrine bitartrate
- OLANZapine
- Octreotide
- Nimotuzumab (SPECIAL ACCESS PROGRAM)
- Omalizumab (NON-FORMULARY)
- Ondansetron
- Oprelvekin (SPECIAL ACCESS PROGRAM)
- Oxaliplatin
- Nusinersen (NON-FORMULARY)
- PACLitaxel (NON-FORMULARY)
- Pamidronate
- Pancuronium bromide
- Pantoprazole sodium
- Onasemnogene abeparvovec-xioi
- Papaverine hydrochloride (NON-FORMULARY)
- Paricalcitol (SPECIAL ACCESS PROGRAM)
- Pegaspargase
- Pegfilgrastim
- Penicillin G sodium
- Pentamidine
- Pentastarch 10% in NS
- Pentostatin (SPECIAL ACCESS PROGRAM)
- PHENobarbital
- Phentolamine mesylate
- Phenylephrine HCl
- Phosphate (sodium phosphate)
- Phytonadione
- Physostigmine salicylate (SPECIAL ACCESS PROGRAM)
- Piperacillin/Tazobactam
- Potassium Chloride
- Procainamide HCl
- Prochlorperazine mesylate
- Propafenone (SPECIAL ACCESS PROGRAM)
- Propofol
- Posaconazole (NON-FORMULARY)
- Propranolol
- Protamine sulphate
- Pralidoxime Chloride (SPECIAL ACCESS PROGRAM)
- Protirelin
- Pyridoxine HCl
- QuiNIDine gluconate (SPECIAL ACCESS PROGRAM)
- QuiNINE Dihydrochloride (SPECIAL ACCESS PROGRAM)
- Rasburicase
- Remifentanil
- Remdesivir
- RiTUXimab
- Rifampin (SPECIAL ACCESS PROGRAM)
- Rocuronium
- Romiplostim (NON-FORMULARY)
- SMOF Lipid 20 %
- SUFentanil
- Rivipansel (STUDY DRUG)
- Salbutamol
- Sargramostim (SPECIAL ACCESS PROGRAM), GM-CSF, NCI #613795
- Scopolamine hydrobromide
- Sodium Chloride 3% (Hypertonic)
- Sodium benzoate
- Sodium bicarbonate
- Sodium thiosulfate
- Streptomycin sulfate (NON-FORMULARY)
- Sodium Acetate
- Sotrovimab
- Succinylcholine chloride
- Sulfamethoxazole and Trimethoprim
- Tacrolimus (NON-FORMULARY)
- Temsirolimus (INVESTIGATIONAL)
- Teniposide
- Thiamine HCl
- Sugammadex
- Thiopental sodium
- Thiotepa (SPECIAL ACCESS PROGRAM)
- Tigecycline (NON-FORMULARY)
- Tobramycin sulphate
- Tocilizumab
- Topotecan (NON-FORMULARY)
- Trabectedin (INVESTIGATIONAL)
- Tranexamic acid
- Trastuzumab
- Tromethamine
- Tuberculin
- Valproic acid (SPECIAL ACCESS PROGRAM)
- Ustekinumab
- Vancomycin
- Vasopressin
- Verapamil HCl
- VinBLAStine
- VinCRIStine
- VinORELbine
- Vedolizumab (NON-FORMULARY)
- Volulyte
- Velaglucerase (NON-FORMULARY)
- Voriconazole (NON-FORMULARY)
- Zidovudine
- Zinc sulfate
- Zoledronic acid
You are here
![]() |
Parenteral Manual |
Drug Monographs
Please be advised that the on-line CHEOnet version of this manual is the most up to date version. All directors responsible for the area need to ensure that the most up to date information is printed and placed in the manual.
The information contained on this website is provided for informational purposes only, as a guide to assist physicians, nurses and other healthcare providers in deciding on the appropriate care required for a particular patient. At all times, physicians, nurses and other healthcare providers must exercise their independent clinical judgment, based on their knowledge, training and experience, taking into account the specific facts and circumstances of each patient, when deciding on the appropriate course of investigation and/or treatment to recommend in a particular clinical situation.
CHEO has made every effort to ensure that the information contained on this website is as current and accurate as possible. However, changes can occur due to ongoing research and the constant influx of new information. Where possible, hospitals and healthcare practitioners should verify the information before acting on it.
Reliance on any information in this website is at the user's own risk. CHEO is not responsible or liable for any harm, loss or other consequences from the use or misuse of the information on this website.